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Cystic Fibrosis (CF) is the most life-threatening genetic disease among the Caucasian population. This disease is caused by a mutation in 
only one gene, the CFTR (Cystic Fibrosis Conductance Regulator) gene. The CFTR acts as a chloride channel, pumping this ion through the 
cell membrane of the epithelial cells that produce mucus. This chloride transport controls the water movement, so it infuences the normal 
mucus production. The lack of the CFTR produces a high reabsortion of water, creating a very sticky and dense mucus that’s very difficult to 
transport. This retention of the mucus leads to recurrent infeccions because the mucus is very rich in nutrients, so it’s a perfect environment 
for the microorganisms to grow [1]. The disease primarily affects the lungs, the digestive and reproductive systems and also the secretory 
glands [2]. This produces various symptoms such as: persistent coughing, shortness of breath, very salty-tasting skin, poor growth and slow 
weight gain, greasy stools and frequent lung infections. The most studied effects are the ones that happen in the lung because of their 
severity and the high mortality rate associated with poor lung function [3].
THE DISEASE:
THE MICROORGANISMS: Bacteria
Pseudomonas aeruginosa: 
• Gram-negative bacillus with very simple nutritional requirements, and it’s 
the most common pathogen in adult CF patients [4]. 
• When P.aeruginosa infects a CF patient it rapidly adapts and begins to 
grow in a biofilm form. Problem→antimicrobial tolerance 10-1.000 times 
higher.  
• Acute infection→highly virulent, but its eradication is possible if the 
antibiotic treatment begins as soon as possible. 
• 20% of the acute infections will develope into a chronic infection that can 
last even a patients lifetime. In this phase, P.aeruginosa has a higher 
antibiotic resistance, and it’s much more difficult to eradicate. [1]
Staphylococcus aureus:
• Gram-positive cocci that agrupates in grape-like clusters, and has a  
typical yellow-gold pigmentation→most common pathogen in  
children/teenagers with CF [4].  
• It’s part of the normal human microbiota, but it’s also the most frequent  
nosocomial pathogen→its prevalence is increasing. 
• Transmission=person to person: direct contact/contaminated objects/aerosols…  
• It can adapt to the CF lungs, and persist intracellularly (protection from the immune system 
and antibiotics) [5].  
• MRSA= Meticillin Resistant Staphylococcus aureus, associated with a decrease in lung 
function→no consensus about the treatment.  
  
Haemophilus influenzae:
• Pleomorphic gram-negative coccobacillus that’s part of the normal 
human respiratory microbiota, but it’s also an important pathogen in 
respiratory and systemic infections. 
• Transmission: direct contact/aerosols.  
• It can cause an infection in CF patients, specially in children, but ends 
up being replaced by P.aeruginosa [6].  
• There’s a vaccine to prevent H.influenzae infections, but it doesn’t work 
with the CF patients. However, it’s a bacteria that responds well to the 
antibiotic treatment.  
Burkholderia cepacia complex:
• A group of gram-negative bacteria that includes different species with  
similar features. They have an extreme nutritional versatility. 
• B.cenocepacia, B.multivorans, B.vietnamensis, B.dolosa and B.cepacia  
can infect CF patients, and they are particularly resistant to antibiotics. 
• In 1/3 of the CF patients infected with these bacteria there’s a decrease in lung function, 
and in an even smaller group there’s a fast decrease in lung function and in general health 
causing even the death of the patients [3]. 
Stenotrophomonas maltophilia:
• A gram-negative bacillus, mobile thanks to the presence of polar flagella. It  
has been isolated with other microorganisms that cause infections in CF  
patients (primarily in patients 16 to 25 years old). 
• It can persist in aqueous, nutrient-poor environments, and it can also live  
forming biofilms in plastic surfaces such as the nebulizers used in aerosol  
therapy. 
• About an 11% of the CF patients are infected with this pathogen, and a chronic infection 
caused by this bacterium is associated with a decrease in lung function [8]. 
• It isn’t a highly virulent pathogen, but it’s emerging as an important nosocomial bacterium. 
Acinetobacter baumannii:
• Gram-negative coccobacillus common in water and soil, but it can be a 
parasite of animals, and it’s involved in nosocomial infections because it’s a 
frequent causative agent of opportunistic infections (as it happens with the 
CF patients). 
• It’s particularly resistant to most antibiotics, so it’s essental to study its  
sensitivity to antibiotics to guide the treatment [7].   
: 
  
Enterobacteriaceae:
• A relatively homogeneous family of gram-negative bacteria. Some of the 
species are part of the human intestinal microbiota [4]. 
• They are occasionally isolated from respiratory secretions from CF 
patients, but they are opportunistic pathogens, and they cause transitory 
infections that aren’t associated with a severe disease.  
• The most frequent are: Escherichia coli, Klebsiella pneumoniae and 
Serratia marcescens.  
New bacteria:
• Genus Pandoraea: it contains  5 named and 4 unnamed species, and basically they have only 
been isolated from respiratory secretions from CF patients. They are gram-negative, and they 
are being considerated as emerging and multi-resistant pathogens in the CF context. There’s 
few clinical data about the pathogenicity of the bacteria, the course of the infection and the 
evolution of the infected patients [9]. 
Fungi
  
Candida:
• Candida albicans and Candida parapsilosis are the most frequently 
isolated yeasts from the CF respiratory secretions. They are part of the 
normal oral microbiota, so they can migrate and then persist in the 
airways of the CF patients. 
• It’s believed that C.albicans could be involved in the decrease of lung 
funtion, and it’s frequently associated with P.aeruginosa [10]. 
Aspergillus fumigatus:
• The most common mold that infects the airways of the CF patients, and it’s  
widely distributed in the environment.  
• Great esporulating capacity, producing small spores (conidia) that can  
penetrate in the airways and stimulate a proinflammatory response in the  
bronchial epithelial cells of the CF patients. This proinflammatory response 
could serve the mold to escape detection by the immune system of the 
patient, thereby allowing the colonization of the respiratory tract. 
• It can cause severe infections after a lung transplant, but they can be  
treated with steroids and antifungal agents [11].  
www.microfq.weebly.com
ANTIBIOTIC RESISTANCE:
Why are microorganisms resistant to certain antibiotics? 
6 main reasons: 
1- The microorganism may be impermeable to the antibiotic. 
2- The microorganism may lack the structure that is inhibited 
by the antibiotic. 
3- The microorganism may change the target of the 
antibiotic, so it can’t exert its effect. 
4- The microorganism can alter the antibiotic inactivating it. 
5- The microorganism can develop an alternative 
biochemical pathway, and therefore, become resistant to the 
antibiotic. 
6- The microorganism may be capable of pumping outwards 
an antibiotic that has penetrated into the cell. [4]  
TREATMENT:
Antibiotic therapy: no consensus treatment. Many strategies have been used by 
changing the route of administration (systemic, oral, inhaled or a combination), the 
types of antibiotics and the duration of the treatment. Inhaled antibiotics have high 
bacteria eradication rates due to the direct delivery of a high antibiotic dose to 
airway space, with limited systemic toxicity. About the oral and intravenous 
antibiotics, currently fluoroquinolones as ciprofloxacin are the most used (but the 
use is limited due to the rapid emergence of resistances) [1].   
Gene therapy: it could be the treatment to cure CF, because its target is the very 
cause of CF, rather than just treating the symptoms and the opportunistic infections. 
Researchers are currently testing aerosol delivery of the normal CFTR gene using 
nebulizers [12].  
Alternative therapy: plant essential oils (cinnamon, clove and thyme) have shown 
antibacterial activity against S.maltophilia, but their toxicity against respiratory 
epithelial cells has yet to be tested [8]. Another alternative is phage therapy, but it 
hasn’t been used yet. 
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